Pharmacokinetics and pharmacodynamics of peptide antibiotics.

Pharmacokinetics and pharmacodynamics of peptide antibiotics.
复制标题

DOI:
10.1016/j.addr.2022.114171
复制
发表时间:
2022-04
影响因子:
16.1
通讯作者:
--
中科院分区:
医学1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

抗微生物药物耐药性是一项重大的全球卫生挑战。由于在不久的将来很少有新的有效抗生素可用,肽抗生素仍然是治疗多重耐药病原体引起的感染的主要治疗选择。合理使用抗生素需要优化不同类型感染的药代动力学和药效学治疗。还必须考虑毒理学,以提高抗生素使用的安全性,并在适当情况下指导治疗药物监测。本文综述了多肽抗生素对多重耐药革兰氏阴性和革兰氏阳性病原体的药代动力学/药效学/毒理学研究进展。优化感染部位的抗生素暴露对于提高其疗效和尽量减少耐药性的出现至关重要。
Antimicrobial resistance is a major global health challenge. As few new efficacious antibiotics will become available in the near future, peptide antibiotics continue to be major therapeutic options for treating infections caused by multidrug-resistant pathogens. Rational use of antibiotics requires optimisation of the pharmacokinetics and pharmacodynamics for the treatment of different types of infections. Toxicodynamics must also be considered to improve the safety of antibiotic use and, where appropriate, to guide therapeutic drug monitoring. This review focuses on the pharmacokinetics/pharmacodynamics/toxicodynamics of peptide antibiotics against multidrug-resistant Gram-negative and Gram-positive pathogens. Optimising antibiotic exposure at the infection site is essential for improving their efficacy and minimising emergence of resistance.
DOI: 10.3390/antibiotics9090573
发表时间: 2020-09-03
期刊: Antibiotics (Basel, Switzerland)
影响因子: --
作者:
Algorri M;Wong-Beringer A
通讯作者: Wong-Beringer A
DOI: 10.3349/ymj.2011.52.4.616
发表时间: 2011-07
影响因子: 2.4
作者:
Ahn BJ;Yim DS;Lee DG;Kwon JC;Kim SH;Choi SM
通讯作者: Choi SM
DOI: 10.1128/aac.02690-16
发表时间: 2017-06-01
影响因子: 4.9
作者:
Ahmed, Maizbha U.;Velkov, Tony;Li, Jian
通讯作者: Li, Jian
DOI: 10.1177/106002808802200404
发表时间: 1988-04-01
期刊: DRUG INTELLIGENCE & CLINICAL PHARMACY
影响因子: --
作者:
ACKERMAN, BH;TAYLOR, EH;PAPPAS, AA
通讯作者: PAPPAS, AA
DOI: 10.3390/ph13030042
发表时间: 2020-03-01
期刊: PHARMACEUTICALS
影响因子: 4.6
作者:
Avila, Maria-Paula;Pacheco, Tatiana;Jaimes, Diego
通讯作者: Jaimes, Diego